Literature DB >> 35870038

Circ_0004676 exacerbates triple-negative breast cancer progression through regulation of the miR-377-3p/E2F6/PNO1 axis.

Guoli Shao1, Xulong Fan2, Pusheng Zhang3, Xuewen Liu1, Lei Huang3, Shufeng Ji4.   

Abstract

BACKGROUND: The significant roles of circular RNAs (circRNAs) in different cancers and diseases have been reported. We now focused on the possible role of a newly recognized circRNA, circ_0004674 in triple-negative breast cancer (TNBC), and the related downstream mechanism.
METHODS: The expression of circ_0004674 in TNBC tissues and cells was determined followed by analysis of the correlation between circ_0004674 and TNBC patients' prognosis. The interaction between circ_0004674, miR-377-3p, E2F6, and PNO1 was then identified using bioinformatics analysis combined with FISH, RIP, RNA pull-down, RT-qPCR, and Western blot analysis. Using gain-of-function and loss-of-function methods, we analyzed the effect of circ_0004674, miR-377-3p, E2F6, and PNO1 on TNBC in vivo and in vitro.
RESULTS: Increased circ_0004674 and E2F6 but decreased miR-377-3p were observed in TNBC tissues and MDA-MB-231 TNBC cells, all of which findings were associated with poor prognosis in patients with TNBC. Silencing of circ_0004676 remarkably suppressed the proliferation, cell cycle progression, and migration of TNBC cells in vitro, as well as inhibiting tumorigenesis and metastasis in vivo. Additionally, circ_0004676 served as a sponge of miR-377-3p which bound to the transcription factor E2F6. In the presence of overexpression of circ_0004676, E2F6 expression and its target PNO1 expression were elevated, while miR-377-3p expression was decreased. Interestingly, overexpression of E2F6 could reverse the inhibitory effect on tumor growth caused by downregulation of circ_0004676.
CONCLUSION: Our study highlighted the carcinogenic effect of circ_0004676 on TNBC through regulation of the miR-377-3p/E2F6/PNO1 axis. 1. Circ_0004674 is highly expressed in TNBC tissues and cells. 2. Circ_0004674 upregulates the expression of E2F6 by sponging miR-377-3p. 3. E2F6 upregulates PNO1 by binding to the PNO1 promoter. 4. Circ_0004674 favors TNBC progression by regulating the miR-377-3p/E2F6/PNO1 axis. 5. This study provides a new target for the treatment of TNBC.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Circ_0004676; E2F6; MicroRNA-377-3p; PNO1; Triple-negative breast cancer

Year:  2022        PMID: 35870038     DOI: 10.1007/s10565-022-09704-6

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.819


  45 in total

1.  Widespread and Functional RNA Circularization in Localized Prostate Cancer.

Authors:  Sujun Chen; Vincent Huang; Xin Xu; Julie Livingstone; Fraser Soares; Jouhyun Jeon; Yong Zeng; Junjie Tony Hua; Jessica Petricca; Haiyang Guo; Miranda Wang; Fouad Yousif; Yuzhe Zhang; Nilgun Donmez; Musaddeque Ahmed; Stas Volik; Anna Lapuk; Melvin L K Chua; Lawrence E Heisler; Adrien Foucal; Natalie S Fox; Michael Fraser; Vinayak Bhandari; Yu-Jia Shiah; Jiansheng Guan; Jixi Li; Michèle Orain; Valérie Picard; Hélène Hovington; Alain Bergeron; Louis Lacombe; Yves Fradet; Bernard Têtu; Stanley Liu; Felix Feng; Xue Wu; Yang W Shao; Malgorzata A Komor; Cenk Sahinalp; Colin Collins; Youri Hoogstrate; Mark de Jong; Remond J A Fijneman; Teng Fei; Guido Jenster; Theodorus van der Kwast; Robert G Bristow; Paul C Boutros; Housheng Hansen He
Journal:  Cell       Date:  2019-02-07       Impact factor: 41.582

Review 2.  Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.

Authors:  Ana C Gregório; Manuela Lacerda; Paulo Figueiredo; Sérgio Simões; Sérgio Dias; João Nuno Moreira
Journal:  Pathol Oncol Res       Date:  2017-09-14       Impact factor: 3.201

Review 3.  Triple-negative breast cancer: epidemiological considerations and recommendations.

Authors:  P Boyle
Journal:  Ann Oncol       Date:  2012-08       Impact factor: 32.976

Review 4.  Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

Authors:  Carsten Denkert; Cornelia Liedtke; Andrew Tutt; Gunter von Minckwitz
Journal:  Lancet       Date:  2016-12-07       Impact factor: 79.321

5.  The RNA binding protein quaking regulates formation of circRNAs.

Authors:  Simon J Conn; Katherine A Pillman; John Toubia; Vanessa M Conn; Marika Salmanidis; Caroline A Phillips; Suraya Roslan; Andreas W Schreiber; Philip A Gregory; Gregory J Goodall
Journal:  Cell       Date:  2015-03-12       Impact factor: 41.582

Review 6.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Authors:  Giampaolo Bianchini; Justin M Balko; Ingrid A Mayer; Melinda E Sanders; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2016-05-17       Impact factor: 66.675

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

8.  Correlation of circular RNA abundance with proliferation--exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues.

Authors:  Anna Bachmayr-Heyda; Agnes T Reiner; Katharina Auer; Nyamdelger Sukhbaatar; Stefanie Aust; Thomas Bachleitner-Hofmann; Ildiko Mesteri; Thomas W Grunt; Robert Zeillinger; Dietmar Pils
Journal:  Sci Rep       Date:  2015-01-27       Impact factor: 4.379

9.  circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a.

Authors:  Rongfang He; Peng Liu; Xiaoming Xie; Yujuan Zhou; Qianjin Liao; Wei Xiong; Xiaoling Li; Guiyuan Li; Zhaoyang Zeng; Hailin Tang
Journal:  J Exp Clin Cancer Res       Date:  2017-10-16

10.  circEPSTI1 as a Prognostic Marker and Mediator of Triple-Negative Breast Cancer Progression.

Authors:  Bo Chen; Weidong Wei; Xiaojia Huang; Xinhua Xie; Yanan Kong; Danian Dai; Lu Yang; Jin Wang; Hailin Tang; Xiaoming Xie
Journal:  Theranostics       Date:  2018-07-01       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.